Immuneering (IMRX) Competitors

Immuneering logo
$3.46 -0.06 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.00 (+0.14%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IMRX vs. ODTX, CRVS, AKTS, PHAR, and MGTX

Should you buy Immuneering stock or one of its competitors? Immuneering's main competitors and comparable companies include Odyssey Therapeutics (ODTX), Corvus Pharmaceuticals (CRVS), Aktis Oncology (AKTS), Pharming Group (PHAR), and MeiraGTx (MGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immuneering compare to Odyssey Therapeutics?

Immuneering (NASDAQ:IMRX) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Odyssey Therapeutics' return on equity of 0.00% beat Immuneering's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -33.91% -32.00%
Odyssey Therapeutics N/A N/A N/A

In the previous week, Immuneering had 5 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 1 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 1.08 beat Immuneering's score of 0.27 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuneering
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Odyssey Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Immuneering is trading at a lower price-to-earnings ratio than Odyssey Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuneeringN/AN/A-$56.03M-$1.03N/A
Odyssey TherapeuticsN/AN/AN/A-$9.13N/A

Immuneering currently has a consensus target price of $15.67, indicating a potential upside of 352.79%. Odyssey Therapeutics has a consensus target price of $34.67, indicating a potential upside of 78.97%. Given Immuneering's stronger consensus rating and higher possible upside, equities analysts clearly believe Immuneering is more favorable than Odyssey Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
Odyssey Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80

67.7% of Immuneering shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Immuneering beats Odyssey Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Immuneering compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Corvus Pharmaceuticals currently has a consensus price target of $32.83, suggesting a potential upside of 222.84%. Immuneering has a consensus price target of $15.67, suggesting a potential upside of 352.79%. Given Immuneering's higher probable upside, analysts clearly believe Immuneering is more favorable than Corvus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corvus Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Immuneering's return on equity of -33.91% beat Corvus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corvus PharmaceuticalsN/A -34.98% -32.67%
Immuneering N/A -33.91%-32.00%

In the previous week, Corvus Pharmaceuticals had 17 more articles in the media than Immuneering. MarketBeat recorded 23 mentions for Corvus Pharmaceuticals and 6 mentions for Immuneering. Immuneering's average media sentiment score of 0.27 beat Corvus Pharmaceuticals' score of 0.12 indicating that Immuneering is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corvus Pharmaceuticals
4 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immuneering
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Corvus Pharmaceuticals has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corvus PharmaceuticalsN/AN/A-$15.28M-$0.71N/A
ImmuneeringN/AN/A-$56.03M-$1.03N/A

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 14.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Immuneering on 7 of the 12 factors compared between the two stocks.

How does Immuneering compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Immuneering has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aktis Oncology$6.50M135.30-$63.73M-$0.82N/A
ImmuneeringN/AN/A-$56.03M-$1.03N/A

28.8% of Aktis Oncology shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aktis Oncology presently has a consensus price target of $35.63, suggesting a potential upside of 118.42%. Immuneering has a consensus price target of $15.67, suggesting a potential upside of 352.79%. Given Immuneering's higher probable upside, analysts plainly believe Immuneering is more favorable than Aktis Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aktis Oncology
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.91
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Immuneering has a net margin of 0.00% compared to Aktis Oncology's net margin of -706.81%. Aktis Oncology's return on equity of -26.86% beat Immuneering's return on equity.

Company Net Margins Return on Equity Return on Assets
Aktis Oncology-706.81% -26.86% -18.13%
Immuneering N/A -33.91%-32.00%

In the previous week, Aktis Oncology had 10 more articles in the media than Immuneering. MarketBeat recorded 16 mentions for Aktis Oncology and 6 mentions for Immuneering. Immuneering's average media sentiment score of 0.27 beat Aktis Oncology's score of -0.23 indicating that Immuneering is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aktis Oncology
2 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immuneering
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Aktis Oncology beats Immuneering on 7 of the 13 factors compared between the two stocks.

How does Immuneering compare to Pharming Group?

Immuneering (NASDAQ:IMRX) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Immuneering had 2 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Immuneering and 4 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.65 beat Immuneering's score of 0.27 indicating that Pharming Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immuneering
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Pharming Group
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pharming Group has a net margin of 6.23% compared to Immuneering's net margin of 0.00%. Pharming Group's return on equity of 8.70% beat Immuneering's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmuneeringN/A -33.91% -32.00%
Pharming Group 6.23%8.70%4.93%

Pharming Group has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmuneeringN/AN/A-$56.03M-$1.03N/A
Pharming Group$376.13M2.27$2.85M$0.3237.69

Immuneering has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.05, meaning that its share price is 105% less volatile than the broader market.

Immuneering currently has a consensus price target of $15.67, indicating a potential upside of 352.79%. Pharming Group has a consensus price target of $39.67, indicating a potential upside of 228.91%. Given Immuneering's stronger consensus rating and higher possible upside, equities analysts plainly believe Immuneering is more favorable than Pharming Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83
Pharming Group
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.60

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 14.9% of Immuneering shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Immuneering and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Immuneering compare to MeiraGTx?

MeiraGTx (NASDAQ:MGTX) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

67.5% of MeiraGTx shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 14.9% of Immuneering shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MeiraGTx has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market.

In the previous week, MeiraGTx had 15 more articles in the media than Immuneering. MarketBeat recorded 21 mentions for MeiraGTx and 6 mentions for Immuneering. Immuneering's average media sentiment score of 0.27 beat MeiraGTx's score of -0.50 indicating that Immuneering is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MeiraGTx
2 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Negative
Immuneering
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

MeiraGTx has a net margin of 19.46% compared to Immuneering's net margin of 0.00%. MeiraGTx's return on equity of 85.23% beat Immuneering's return on equity.

Company Net Margins Return on Equity Return on Assets
MeiraGTx19.46% 85.23% 24.12%
Immuneering N/A -33.91%-32.00%

Immuneering has lower revenue, but higher earnings than MeiraGTx. Immuneering is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MeiraGTx$81.39M10.16-$114.20M$0.8010.58
ImmuneeringN/AN/A-$56.03M-$1.03N/A

MeiraGTx presently has a consensus target price of $24.00, indicating a potential upside of 183.69%. Immuneering has a consensus target price of $15.67, indicating a potential upside of 352.79%. Given Immuneering's stronger consensus rating and higher probable upside, analysts clearly believe Immuneering is more favorable than MeiraGTx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MeiraGTx
0 Sell rating(s)
3 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.63
Immuneering
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.83

Summary

MeiraGTx beats Immuneering on 9 of the 16 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMRX vs. The Competition

MetricImmuneeringBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$227.97M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-3.3625.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book1.334.184.463.72
Net Income-$56.03M-$24.15M$3.52B$393.10M
7 Day Performance-10.13%-7.25%-5.47%-4.73%
1 Month Performance-3.62%-5.98%-4.57%-7.14%
1 Year Performance-50.00%-7.72%-1.79%-7.51%

Immuneering Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMRX
Immuneering
2.3136 of 5 stars
$3.46
-1.7%
$15.67
+352.8%
-44.6%$227.97MN/AN/A65
ODTX
Odyssey Therapeutics
2.3771 of 5 stars
$20.21
+5.5%
$34.67
+71.5%
N/A$971.29MN/AN/A100
CRVS
Corvus Pharmaceuticals
2.8083 of 5 stars
$11.38
+0.3%
$32.83
+188.5%
+20.9%$957.29MN/AN/A37
AKTS
Aktis Oncology
1.5758 of 5 stars
$17.53
+7.1%
$35.63
+103.2%
N/A$942.24M$6.50MN/A79
PHAR
Pharming Group
3.8264 of 5 stars
$13.22
+0.4%
$39.67
+200.1%
-25.1%$935.50M$376.13M41.30407

Related Companies and Tools


This page (NASDAQ:IMRX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners